US · RNAC
Cartesian Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Watertown, MA 02472
- Website
- selectabio.com
Price · as of 2024-12-31
$6.22
Market cap 197.37M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $47.46 | +663.02% |
| Intrinsic Value(DCF) | $8.22 | +32.15% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | $0.00 | $0.00 | |||
| 2016 | $419.40 | $358.28 | $88.38 | $0.00 | $0.00 |
| 2017 | $332.10 | $180.34 | $0.00 | $0.00 | $9,790.15 |
| 2018 | $69.00 | $27.60 | $7,189.84 | $0.00 | $0.00 |
| 2019 | $115.80 | $46.32 | $14,525,558.53 | $0.00 | $0.00 |
| 2020 | $128.10 | $835.64 | $79,056,379.23 | $0.00 | $0.00 |
| 2021 | $49.50 | $1,288.47 | $25,700,876.06 | $0.00 | $0.00 |
| 2022 | $41.10 | $226.62 | $346,272.33 | $67.33 | $325.69 |
| 2023 | $19.20 | $81.92 | $0.00 | $0.00 | $2,768.05 |
| 2024 | $18.40 | $47.46 | $1.18 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Cartesian Therapeutics, Inc.'s (RNAC) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $47.46
- Current price
- $6.22
- AI upside
- +663.02%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$8.22
+32.15% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| RNAC | Cartesian Therapeutics, I… | $6.22 | 197.37M | +663% | +32% | — | — | -6.16 | -70.08 | 12.25 | -3.66 | — | -2.32 | 100.00% | -112.81% | -198.97% | 34.64% | 12.34% | -20.92% | -2.06 | — | 9.43 | 9.29 | 2.61 | -9339.00% | 4964.00% | -3621.00% | -6.87% | -1.03 | 9.21% | 0.00% | 0.00% | 27.83% | -6.33 | -8.48 | 7.14 | -1.29 |
| AARD | Aardvark Therapeutics, In… | $12.49 | 271.95M | — | — | — | — | -6.35 | -2.39 | — | -2.56 | -3.45 | -2.39 | 0.00% | — | — | 46.03% | 26.47% | -46.77% | -0.01 | — | 15.05 | 14.95 | 2.69 | 18393.00% | — | 21243.00% | -13.91% | -3.67 | 21.14% | 0.00% | 0.00% | 39.22% | -2.54 | -3.18 | — | -0.36 |
| AVTX | Avalo Therapeutics, Inc. | $17.50 | 197.65M | -16% | -59% | — | +1,518% | -1.80 | 0.47 | 143.03 | 1.04 | — | 0.51 | 182.99% | -15535.60% | -7965.76% | -50.06% | 26350.77% | -40.91% | 0.00 | — | 19.96 | 19.42 | 1.96 | -9713.00% | -7708.00% | 5908.00% | -77.77% | -7.05 | 18867.69% | 0.00% | 0.00% | 201.50% | 1.03 | 1.45 | -160.77 | -1.75 |
| EPRX | Eupraxia Pharmaceuticals … | $8.18 | 273.87M | — | — | — | — | -5.48 | 4.23 | — | -3.01 | — | 4.23 | 0.00% | — | — | -144.55% | 1233.17% | -93.26% | 0.00 | -44.74 | 11.10 | 10.74 | 0.92 | -3504.00% | — | 4455.00% | -21.32% | -9.67 | 955.80% | 0.00% | 0.00% | 17.10% | -2.78 | -3.59 | — | 19.45 |
| FENC | Fennec Pharmaceuticals In… | $8.49 | 233.9M | +1,836% | +110,254% | — | — | -430.69 | -31.98 | 3.95 | 37.62 | — | -31.98 | 93.30% | 5.40% | -0.92% | 4.98% | -72.31% | -1.21% | -3.29 | 0.63 | 6.38 | 5.71 | -1.52 | -9733.00% | 12369.00% | -25738.00% | 14.37% | 3.90 | -759.68% | 0.00% | 0.00% | 13.40% | 70.28 | 6.69 | 3.80 | -2.39 |
| GNFT | Genfit S.A. | $10.00 | 497.97M | +550% | -76% | -82% | -52% | 103.96 | 2.26 | 2.34 | 16.42 | — | 7.38 | 99.55% | 4.90% | 2.25% | 2.20% | 4.87% | 0.93% | 0.90 | 0.69 | 1.23 | 1.19 | -2.36 | -10517.00% | 13456.00% | -12455.00% | 9.08% | 0.20 | 25.88% | 0.00% | 0.00% | 7.69% | 41.76 | 9.63 | 2.04 | -1.81 |
| IVA | Inventiva S.A. | $6.49 | 337.36M | +349% | -81% | — | +2,278% | -0.75 | -1.30 | 15.02 | -0.58 | -1.64 | -1.29 | 100.00% | -1060.64% | -2002.74% | 265.67% | 114.26% | -195.42% | -0.51 | -8.01 | 0.92 | 0.90 | 0.25 | 4568.00% | -4737.00% | 500.00% | -62.45% | -0.71 | 101.03% | 0.00% | 0.00% | 38.23% | -0.98 | -1.11 | 10.43 | -4.52 |
| MDWD | MediWound Ltd. | $17.30 | 187.92M | +19% | -58% | — | — | -5.58 | 5.41 | 8.34 | -4.71 | -1.84 | 5.43 | 8.81% | -95.85% | -149.46% | -96.33% | 446.97% | -43.19% | 0.22 | -34.55 | 1.97 | 1.85 | 0.08 | 30400.00% | 822.00% | 1753.00% | -11.80% | -0.51 | 458.83% | 0.00% | 0.00% | 0.00% | -6.83 | -6.65 | 6.55 | -1.69 |
| NAUT | Nautilus Biotechnology, I… | $2.42 | 305.66M | — | — | — | — | -4.96 | 1.87 | — | -4.18 | — | 1.87 | 0.00% | — | — | -32.27% | -69.30% | -27.20% | 0.19 | — | 13.33 | 13.00 | -0.34 | -1607.00% | — | -1517.00% | -17.74% | -6.38 | -53.89% | 0.00% | 0.00% | 0.05% | -3.28 | -4.22 | — | 2.18 |
| NTHI | Neonc Technologies Holdin… | $10.22 | 198.27M | — | — | — | — | — | — | — | — | — | — | 100.00% | -8605.45% | -14335.50% | 122.08% | 110.23% | -508.20% | 0.00 | -2.64 | 0.25 | 0.02 | 0.00 | -2125.00% | 1779.00% | 12414.00% | — | -0.47 | 65.03% | — | 0.00% | — | — | — | — | — |
| OBIO | Orchestra BioMed Holdings… | $4.38 | 247.32M | +415% | -61% | — | — | -2.55 | 4.73 | 59.04 | -1.65 | -20.99 | 4.73 | 92.27% | -2437.49% | -2313.27% | -120.84% | 365.45% | -71.21% | 0.50 | — | 4.27 | 4.13 | 0.09 | 1216.00% | -442.00% | 1005.00% | -32.65% | -3.12 | 288.99% | 0.00% | 0.00% | 0.00% | -1.64 | -2.07 | 39.98 | -5.45 |
About Cartesian Therapeutics, Inc.
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
- CEO
- Carsten Brunn
- Employees
- 66
- Beta
- 0.41
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($8.22 ÷ $6.22) − 1 = +32.15% (DCF, example).